2017 DTRF Desmoid Tumor Research Workshop
Sunday, September 24, 2017
(Tentative agenda as of 8.10.17)

7:15-8:00  Continental breakfast and informal introductions.
8:00-8:05  Welcome: Jeanne Whiting, President & Co-Founder, DTRF.
8:05-8:20  David Kirsch, MD, PhD, Barbara Levine University Professor and Vice Chair for Basic & Translational Research, Department of Radiation Oncology Professor, Department of Pharmacology & Cancer Biology, Duke University, “Using radiation therapy to treat desmoid tumors.”
8:20-8:35  Tom van Cann, MD, Medical oncologist, KU Leuven, “Systemic treatment preferences for patients with advanced desmoid-type firomatosis in Europe.”
8:35-8:50  Yuhong Zhou, MD, PhD, Professor & Oncologist, Zhongshan Hospital, Fudan University, “The treatments and clinical outcomes of sporadic and fap-associated desmoid tumor: a single centre long-term observational study.”
8:50-9:05  Milea J.M. Timbergen, MD, PhD candidate, Erasmus Medical Center, “Results of the interim analysis of the Dutch GRAFITI study.”
9:05-9:20  Breelyn Wilky, MD, Assistant Professor in Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, “Mutation phenotypes and their responses to chemotherapy.”
9:20-9:35  Discussion
9:50-10:05 Yoshihiro Nishida, MD, PhD, Associate Professor, Nagoya University Graduate School of Medicine, “Effects of mechanical forces on the cell behavior of desmoid-type fibromatosis.”
10:05-10:20 Danielle Braggio, PhD, Post-Doctoral Researcher, Ohio State University, “Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.”
10:20-10:35 Kris Vlemingckx, PhD, Professor, Department of Molecular Biomedical Research Unit of Developmental Biology VIB, Ghent University, “Therapeutic target identification in a Xenopus model for desmoid tumor formation – an update.”
10:35-10:50 Gerlinde Wernig, MD, Assistant Professor of Pathology, Stanford University, “Unifying mechanism on different fibrotic diseases.”
10:50-11:05  Discussion
11:05-11:40  TBD
11:40-11:45  Steve Horrigan, PhD, Chief Scientific Officer, Beta Cat Pharmaceuticals, “Tegavivint (BC2059) – A new way of attacking beta catenin driven disease.”
11:45-11:55  Danielle Braggio, PhD, Post-Doctoral Researcher in Sarcomas, Ohio State University, “Tegavivint (BC2059) studies in desmoid cell lines.”
11:55- 12:05  Benjamin Alman, MD, Professor and Chair, Department of Orthopaedic Surgery, Duke University, “Tegavivint (BC2059) studies in Apc(+)/Apc(1638N) genetic mouse model of aggressive fibromatosis.”

12:05- 12:15  Casey Cunningham, MD, Chief Medical Officer, Beta Cat Pharmaceuticals, “Synopsis of a Planned Phase 1/2 Study of Tegavivant (BC2059) in Desmoid Tumors.”

12:15- 12:45  Lunch break- continue discussion

12:45- 1:45  Lunch

1:45- 2:10  Benjamin Alman, MD, Department Chair, Orthopedic Surgery, Duke University, “Introduction and report on Collaboration for a Cure project.”


2:25-2:40  Aaron Weiss, DO, Maine Medical Center, “Development of a DTRF-Sponsored Virtual Tumor Board.”

2:40- 2:50  Kelly Mercier, PhD, RTI International, “DTRF Natural History Study and Patient Registry Launch and Update.”

2:50-4:00  SUMMARY DISCUSSION and SETTING OF PRIORITIES